Charles Herzog, Charles A. Herzog, M.D., FACC, FAHA
Charles A. Herzog, MD, FACC, FAHA (Minneapolis, MN, USA)
Dr. Charles Herzog is professor of medicine, University of Minnesota, and cardiologist at Hennepin County Medical Center (HCMC)/Hennepin Healthcare for 42 years. He founded the program in interventional cardiology at HCMC and served as cardiac catheterization laboratory director (1985-1991), and cardiac ultrasound laboratory director (1997-2012).
He directed the USRDS Cardiovascular Special Studies Center from 1999-2014. He participated in the development of the NKF K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients and KDIGO Clinical Practice Guidelines on Acute Kidney Injury, and three AHA Scientific Statements related to kidney and heart disease. He co-chaired the 2010 KDIGO Cardiovascular/CKD Controversies Conference, and was planning co-chair of the KDIGO Kidney, Heart, and Vascular Conference Series (2016-2020), and currently is on the ISN cardio-kidney tool kit steering committee. He has chaired the Renal Committee of the ISCHEMIA-CKD Trial and Critical Event Commitee of the CARSK Trial , and serves on the steering committee of the CARSK and RENAISSANCE trials.. He has been actively involved in clinical trials involving patients with CKD and cardiovascular disease for the past 26 years.
He has 325 published manuscripts. His special interests include heart disease in CKD patients and echocardiography.
Financial relationships
-
Attribution:SelfType of financial relationship:Individual stocks and stock optionsIneligible company:Boston ScientificTopic:Cardiac device therapyDate added:10/25/2026Date updated:10/25/2026Relationship end date:01/01/2027
-
Attribution:SelfType of financial relationship:Individual stocks and stock optionsIneligible company:Johnson&JohnsonTopic:PharmaceuticalsDate added:10/25/2026Date updated:10/25/2026Relationship end date:01/01/2027
-
Attribution:SelfType of financial relationship:Individual stocks and stock optionsIneligible company:MerckTopic:PharmaceuticalsDate added:10/25/2026Date updated:10/25/2026Relationship end date:01/01/2027
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:MerckTopic:PharmaceuticalsDate added:10/25/2026Date updated:10/25/2026Relationship end date:12/31/2025
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:Novo NordiskTopic:PharmaceuticalsDate added:10/25/2026Date updated:10/25/2026Relationship end date:01/01/2028
-
Attribution:SelfType of financial relationship:Individual stocks and stock optionsIneligible company:PfizerTopic:PharmaceuticalsDate added:10/25/2026Date updated:10/25/2026Relationship end date:01/01/2028
-
Attribution:SelfType of financial relationship:Royalties or patent beneficiaryIneligible company:UpToDateTopic:CKD and Heart DiseaseDate added:10/25/2026Date updated:10/25/2026Relationship end date:01/01/2029
-
Attribution:SelfType of financial relationship:ConsultantIneligible company:Astra-ZenecaTopic:PharmaceuticalsDate added:10/25/2026Date updated:10/25/2026Relationship end date:12/31/2029

Facebook
X
LinkedIn
Forward